Literature DB >> 29242726

Relationship Between Dual Time Point FDG PET/CT and Clinical Prognostic Indexes in Patients with High Grade Lymphoma: a Pilot Study.

Do Hyoung Lim1, Jai Hyuen Lee2.   

Abstract

PURPOSE: This study investigated the correlative relationship between metabolic parameters estimated from dual time point 2-deoxy-2-[18F] fluoro-D-glucose (18F-FDG) positron emission tomography/computerized tomography (PET/CT) and the clinical tools predicting the outcome of a lymphoma. We also measured metabolic and volumetric alterations between early and delayed 18F-FDG PET/CT in patients with high grade lymphoma (HGL).
METHODS: The samples were 122 lymph nodes and extralymphatic lesions from 26 patients diagnosed with HGL. All patients were applied to the International Prognostic Index (IPI), Ann Arbor stage, and revised IPI as clinical prognostic parameters. 18F-FDG dual time point PET/CT (DTPFP) consisted of an early scan 1 h after 18F-FDG injection and a delayed scan 2 h after the early scan. Based on an analysis of DTPFP, we estimated the standardized uptake value (SUV) of tumors from the early and delayed scans, retention index (RI) representing the percentage change between early and delayed SUV, and metabolic volume different index (MVDI) calculated using metabolic tumor volumes (MTV).
RESULTS: RImax showed a multiple positive correlative relationship with stage and IPI in lesion-by-lesion analysis (p < 0.01). In the case of IPI, the high risk group exhibited higher RImax than the low risk group (p = 0.004). In the case of revised IPI, the RImax of the low risk group were significantly lower than the intermediate and high risk groups, respectively (p < 0.01). The MVDIs of the best outcome group were decreased in comparison to the moderate outcome group (p = 0.029). There was a significant negative correlative relationship between RImax and MVDI, and the inclinations for decreased MVDIs were slightly associated with increased RIs.
CONCLUSIONS: RImax extracted from DTPFP had a significant relationship to extranodal involvement, staging, IPI, and revised IPI. MVDI showed significant negative correlation with RImax. Further large scale studies are warranted to support and extend these preliminary results.

Entities:  

Keywords:  Fluorine 18-fluorodeoxyglucose (FDG); International prognostic index; Lymphoma; Metabolic tumor volume; Positron emission tomography/computed tomography (PET/CT)

Year:  2017        PMID: 29242726      PMCID: PMC5721088          DOI: 10.1007/s13139-017-0480-y

Source DB:  PubMed          Journal:  Nucl Med Mol Imaging        ISSN: 1869-3474


  32 in total

Review 1.  Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group.

Authors:  B D Cheson; S J Horning; B Coiffier; M A Shipp; R I Fisher; J M Connors; T A Lister; J Vose; A Grillo-López; A Hagenbeek; F Cabanillas; D Klippensten; W Hiddemann; R Castellino; N L Harris; J O Armitage; W Carter; R Hoppe; G P Canellos
Journal:  J Clin Oncol       Date:  1999-04       Impact factor: 44.544

2.  Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium.

Authors:  Gilles Salles; Daphne de Jong; Wanling Xie; Andreas Rosenwald; Mukesh Chhanabhai; Philippe Gaulard; Wolfram Klapper; Maria Calaminici; Birgitta Sander; Christoph Thorns; Elias Campo; Thierry Molina; Abigail Lee; Michael Pfreundschuh; Sandra Horning; Andrew Lister; Laurie H Sehn; John Raemaekers; Anton Hagenbeek; Randy D Gascoyne; Edie Weller
Journal:  Blood       Date:  2011-05-02       Impact factor: 22.113

3.  [Dual-time point images of the liver with (18)F-FDG PET/CT in suspected recurrence from colorectal cancer].

Authors:  D Fuster; S Lafuente; X Setoain; I Navales; A Perissinotti; J Pavia; P Paredes; F Lomeña; F Pons
Journal:  Rev Esp Med Nucl Imagen Mol       Date:  2011-12-07       Impact factor: 1.359

4.  Potential novel application of dual time point SUV measurements as a predictor of survival in head and neck cancer.

Authors:  Bal Sanghera; Wai Lup Wong; Martin A Lodge; Sharon Hain; David Stott; John Lowe; Catherine Lemon; Kate Goodchild; Michele Saunders
Journal:  Nucl Med Commun       Date:  2005-10       Impact factor: 1.690

5.  Prognostic Significance of Intratumoral Metabolic Heterogeneity on 18F-FDG PET/CT in Pathological N0 Non-Small Cell Lung Cancer.

Authors:  Do-Hoon Kim; Ji-Hoon Jung; Seung Hyun Son; Choon-Young Kim; Chae Moon Hong; Jong-Ryool Oh; Shin Young Jeong; Sang-Woo Lee; Jaetae Lee; Byeong-Cheol Ahn
Journal:  Clin Nucl Med       Date:  2015-09       Impact factor: 7.794

6.  Intratumor heterogeneity characterized by textural features on baseline 18F-FDG PET images predicts response to concomitant radiochemotherapy in esophageal cancer.

Authors:  Florent Tixier; Catherine Cheze Le Rest; Mathieu Hatt; Nidal Albarghach; Olivier Pradier; Jean-Philippe Metges; Laurent Corcos; Dimitris Visvikis
Journal:  J Nucl Med       Date:  2011-02-14       Impact factor: 10.057

7.  FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma.

Authors:  N G Mikhaeel; M Hutchings; P A Fields; M J O'Doherty; A R Timothy
Journal:  Ann Oncol       Date:  2005-06-24       Impact factor: 32.976

8.  Dual-time-point FDG PET/CT for the evaluation of pediatric tumors.

Authors:  Danny L Costantini; Reza Vali; Jeffery Chan; Susan McQuattie; Martin Charron
Journal:  AJR Am J Roentgenol       Date:  2013-02       Impact factor: 3.959

9.  Evaluation of dual-time-point 18F-FDG PET for staging in patients with lung cancer.

Authors:  Daisuke Uesaka; Yoshiki Demura; Takeshi Ishizaki; Shingo Ameshima; Isamu Miyamori; Masato Sasaki; Yasuhisa Fujibayashi; Hidehiko Okazawa
Journal:  J Nucl Med       Date:  2008-09-15       Impact factor: 10.057

10.  International prognostic index-based outcomes for diffuse large B-cell lymphomas.

Authors:  Richard B Wilder; Maria A Rodriguez; L Jeffrey Medeiros; Susan L Tucker; Chul S Ha; Jorge E Romaguera; Barbara Pro; Mark A Hess; Fernando Cabanillas; James D Cox
Journal:  Cancer       Date:  2002-06-15       Impact factor: 6.860

View more
  5 in total

1.  Prognostic value of metabolic parameters measured by pretreatment dual-time-point 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with intrahepatic or perihilar cholangiocarcinoma: A STROBE study.

Authors:  Jae Pil Hwang; Jong Ho Moon; Hee Kyung Kim; Min Hee Lee; Chae Hong Lim; Soo Bin Park; Joon-Kee Yoon; Jung Mi Park
Journal:  Medicine (Baltimore)       Date:  2021-05-28       Impact factor: 1.817

2.  Dual-time-point PET/CT study protocol can improve the larynx cancer diagnosis.

Authors:  Agata Karolina Pietrzak; Joanna Kazmierska; Andrzej Marszalek; Pawel Golusinski; Aleksandra Heydrych; Katarzyna Wiechec; Witold Cholewinski
Journal:  Rep Pract Oncol Radiother       Date:  2020-04-28

3.  A prospective study on dual time 18F-FDG-PET/CT in high-risk prostate cancer patients.

Authors:  Mike Allan Mortensen; Mie Holm Vilstrup; Mads Hvid Poulsen; Oke Gerke; Poul Flemming Høilund-Carlsen; Lars Lund
Journal:  BMC Res Notes       Date:  2018-12-07

4.  Dual time point 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.

Authors:  Yoji Yamagishi; Tomomi Koiwai; Tamio Yamasaki; Takahiro Einama; Makiko Fukumura; Miyuki Hiratsuka; Takako Kono; Katsumi Hayashi; Jiro Ishida; Hideki Ueno; Hitoshi Tsuda
Journal:  BMC Cancer       Date:  2019-11-27       Impact factor: 4.430

5.  Clinical Impact of Dual Time Point 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Fusion Imaging in Pancreatic Cancer.

Authors:  Takahiro Einama; Yoji Yamagishi; Yasuhiro Takihata; Fukumi Konno; Kazuki Kobayashi; Naoto Yonamine; Ibuki Fujinuma; Takazumi Tsunenari; Keita Kouzu; Akiko Nakazawa; Toshimitsu Iwasaki; Eiji Shinto; Jiro Ishida; Hideki Ueno; Yoji Kishi
Journal:  Cancers (Basel)       Date:  2022-07-28       Impact factor: 6.575

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.